Publications

@article{Koita2024,

title = {Increasing the uptake of Intermittent Preventive Treatment of malaria in pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP) through seasonal malaria chemoprevention channel delivery: protocol of a multicenter cluster randomized implementation trial in Mali and Burkina Faso},

author = {Kadiatou Koita and Joel D. Bognini and Efundem Agboraw and Mahamadou Demb\'{e}l\'{e} and Seydou Yabr\'{e} and Bi\'{e}bo Bihoun and Oumou Coulibaly and Hamidou Niangaly and Jean Batiste N’Takp\'{e} and Maia Lesosky and Dario Scaramuzzi and Eve Worrall and Jenny Hill and Val\'{e}rie Briand and Halidou Tinto and Kassoum Kayentao},

url = {https://pubmed.ncbi.nlm.nih.gov/38166711/},

doi = {10.1186/S12889-023-17529-Z},

issn = {1471-2458},

year  = {2024},

date = {2024-01-01},

journal = {BMC public health},

volume = {24},

issue = {1},

publisher = {BMC Public Health},

abstract = {Background: The uptake of Intermittent Preventive Treatment of malaria in pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP) remains unacceptably low, with more than two-thirds of pregnant women in sub-Saharan Africa still not accessing the three or more doses recommended by the World Health Organisation (WHO). In contrast, the coverage of Seasonal Malaria Chemoprevention (SMC), a more recent strategy recommended by the WHO for malaria prevention in children under five years living in Sahelian countries with seasonal transmission, including Mali and Burkina-Faso, is high (up to 90%). We hypothesized that IPTp-SP delivery to pregnant women through SMC alongside antenatal care (ANC) will increase IPTp-SP coverage, boost ANC attendance, and increase public health impact. This protocol describes the approach to assess acceptability, feasibility, effectiveness, and cost-effectiveness of the integrated strategy. Methods and analysis: This is a multicentre, cluster-randomized, implementation trial of IPTp-SP delivery through ANC + SMC vs ANC alone in 40 health facilities and their catchment populations (20 clusters per arm). The intervention will consist of monthly administration of IPTp-SP through four monthly rounds of SMC during the malaria transmission season (July to October), for two consecutive years. Effectiveness of the strategy to increase coverage of three or more doses of IPTp-SP (IPTp3 +) will be assessed using household surveys and ANC exit interviews. Statistical analysis of IPT3 + and four or more ANC uptake will use a generalized linear mixed model. Feasibility and acceptability will be assessed through in-depth interviews and focus group discussions with health workers, pregnant women, and women with a child \< 12 months. Discussion: This multicentre cluster randomized implementation trial powered to detect a 45% and 22% increase in IPTp-SP3 + uptake in Mali and Burkina-Faso, respectively, will generate evidence on the feasibility, acceptability, effectiveness, and cost-effectiveness of IPTp-SP delivered through the ANC + SMC channel. The intervention is designed to facilitate scalability and translation into policy by leveraging existing resources, while strengthening local capacities in research, health, and community institutions. Findings will inform the local national malaria control policies. Trial registration: Retrospectively registered on August 11th, 2022; registration # PACTR202208844472053. Protocol v4.0 dated September 04, 2023. Trail sponsor: University of Sciences Techniques and Technologies of Bamako (USTTB), Mali.},

keywords = {Antimalarials* / therapeutic use, Burkina Faso, Chemoprevention, Child, Clinical Trial Protocol, doi:10.1186/s12889-023-17529-z, Drug Combinations, Female, Humans, Joel D Bognini, Kadiatou Koita, Kassoum Kayentao, Malaria* / drug therapy, Malaria* / prevention \& control, Mali, MEDLINE, Multicenter Studies as Topic, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, Non-U.S. Gov't, Parasitic* / prevention \& control, PMC10763117, pmid:38166711, Pregnancy, Pregnancy Complications, Preschool, PubMed Abstract, Pyrimethamine / therapeutic use, Randomized Controlled Trials as Topic, Research Support, Seasons, Sulfadoxine / therapeutic use},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile},

author = {Myriam El Gaaloul and Andre Marie Tchouatieu and Kassoum Kayentao and Brice Campo and Benedicte Buffet and Hanu Ramachandruni and Jean Louis Ndiaye and Timothy N. C. Wells and Celine Audibert and Jane Achan and Cristina Donini and Hellen C. Barsosio and Halidou Tinto},

url = {https://pubmed.ncbi.nlm.nih.gov/39425110/},

doi = {10.1186/S12936-024-05128-1},

issn = {1475-2875},

year  = {2024},

date = {2024-01-01},

journal = {Malaria journal},

volume = {23},

issue = {1},

pages = {315},

publisher = {Malar J},

abstract = {\<p\>Malaria is preventable, but the burden of disease remains high with over 249 million cases and 608,000 deaths reported in 2022. Historically, the most important protective interventions have been vector control and chemopreventive medicines with over 50 million children receiving seasonal malaria chemoprevention in the year 2023. Two vaccines are approved and starting to be deployed, bringing additional protection for children up to 36 months. However, the impact of these currently available tools is somewhat limited on various fronts. Vaccines exhibit partial efficacy, are relatively costly, and not accessible in all settings. The challenges encountered with chemoprevention are barriers to acceptability and feasibility, including frequency of dosing, and the lack of options in the first trimester of pregnancy and for women living with HIV. Also, the emergence of resistance against chemopreventive medicines is concerning. To address these limitations, a target product profile (TPP) is proposed as a road map to guide innovation and to boost the quest for novel chemopreventive alternatives. This TPP describes the ideal product attributes, while acknowledging potential trade-offs that may be needed. Critically, it considers the target populations most at risk; primarily infants, children, and pregnant women. Malaria control and elimination requires appropriate chemoprevention, not only in areas of high endemicity and transmission, but also in lower transmission areas where immunity is declining, as well as for travellers from areas where malaria has been eliminated. New medicines should show acceptable safety and tolerability, with high and long protective efficacy. Formulations and costs need to support operational adherence, access, and effectiveness. Next generation long-acting oral and injectable drugs are likely to constitute the backbone of malaria prevention. Therefore, the perspectives of front-line experts in malaria prevention, researchers, and those involved in drug development are captured in the TPP. This inclusive approach aims at concentrating efforts and aligning responses across the community to develop new and transformative medicines.\</p\>},

keywords = {Administration, Andre Marie Tchouatieu, Antimalarials* / administration \& dosage, Antimalarials* / therapeutic use, Chemoprevention* / methods, doi:10.1186/s12936-024-05128-1, Female, Halidou Tinto, Humans, Injections, Malaria* / prevention \& control, MEDLINE, Myriam El Gaaloul, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, Oral, PMC11490162, pmid:39425110, Pregnancy, PubMed Abstract, Review},

pubstate = {published},

tppubtype = {article}

}

@article{Tahita2024,

title = {Post-discharge malaria chemoprevention in children with severe anaemia: a robust strategy to save lives},

author = {Marc Christian Tahita and Quique Bassat},

url = {https://pubmed.ncbi.nlm.nih.gov/38097287/},

doi = {10.1016/S2214-109X(23)00524-7},

issn = {2214-109X},

year  = {2024},

date = {2024-01-01},

journal = {The Lancet. Global health},

volume = {12},

issue = {1},

pages = {e2-e3},

publisher = {Lancet Glob Health},

keywords = {Aftercare, Anemia* / epidemiology, Anemia* / prevention \& control, Antimalarials* / therapeutic use, Chemoprevention, Child, Humans, Infant, Malaria* / drug therapy, Malaria* / prevention \& control, Marc Christian Tahita, MEDLINE, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, Patient Discharge, pmid:38097287, PubMed Abstract, Quique Bassat},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Prevalence of and risk factors for microscopic and submicroscopic malaria infections in pregnancy: a systematic review and meta-analysis},

author = {Anna Maria Eijk and Kasia Stepniewska and Jenny Hill and Steve M. Taylor and Stephen J. Rogerson and Gilles Cottrell and R. Matthew Chico and Julie R. Gutman and Halidou Tinto and Holger W. Unger and Stephanie K. Yanow and Steven R. Meshnick and Feiko O. Kuile and Alfredo Mayor and Steve M. Taylor and Stephen J. Rogerson and R. Matthew Chico and Julie R. Gutman and Hallidou Tinto and Holger W. Unger and Stephanie K. Yanow and Manfred Accrombessi and Ayola A. Adegnika and Rukhsana Ahmed and Eliana Mar\'{i}a Arango-Fl\'{o}rez and Myriam Arevalo-Herrera and Emmanual Arinaitwe and Paulo Arnaldo and Per Ashorn and Ulla Ashorn and Azucena Bardaji and Inoni Betuela and Praveen K. Bharti and Francis Bohissou and Camila B\^{o}tto-Menezes and Vera Braun and Valerie Briand and Jessica Briggs and Mar\'{i}a Eugenia Castellanos and Daniel Chandramohan and Enesia Banda Chaponda and Chetan Chitnis and Lauren M. Cohee and Michel Cot and Umberto d'Alessandro and Lise Denoeud-Ndam and Meghna Desai and Alassane Dicko and Xavier Ding and Grant Dorsey and Patrick E. Duffy and Maha A. Elbadry and Sonia M. Enosse and Yue Fan and Nadine Fievet and Michal Fried and Blaise Genton and Raquel Gonzalez and Brian Greenwood and Linda Kalilani and Johanna H. Kattenberg and Kassoum Kayentao and Carole Khairallah and Christopher L. King and Dhanpat Kumar Kochar and Swati Kochar and Felix Koukouikila-Koussounda and Sarah H. Landis and Miriam K. Laufer and Rose F. Leke and Eusebio Macete and Sonia Maculuve and Mwayiwawo Madanitsa and Almahamoudou Mahamar and Ken Maleta and Indu Malhotra and Rella Zoleko Manego and Flor Ernestina Martinez-Espinosa and Achille Massougbodji and Don Mathanga and Michela Menegon and Clara Menendez and Petra Mens and Martin Meremikwu and Frank P. Mockenhaupt and Ghyslain Mombo-Ngoma and Dominic Mosha and Ivo Mueller and Alain Nahum and Paul Natureeba and Nicaise Ndam and Francine Ntoumi and Olabisi A. Oduwole and Bernard A. Okech and Maria Ome-Kaius and Kephas Otieno and Norma Padilla and Michal Ramharter and Rosemary Rochford and Anna Rosanas-Urgell and Maria Ruperez and Katherine R. Sabourin and Sergi Sanz and Henk D. Schallig and Susana Scott and Esperanca Sevene and Carlo Severini and Harry Tagbor and Diane Wallace Taylor and Maminata Traore Coulibaly and Ana Vasquez and Annie Walker-Abbey and Blair J. Wylie and Djimon M. Zannou and Stephen R. Meshnick},

url = {https://pubmed.ncbi.nlm.nih.gov/37276878/},

doi = {10.1016/S2214-109X(23)00194-8},

issn = {2214-109X},

year  = {2023},

date = {2023-01-01},

journal = {The Lancet. Global health},

volume = {11},

issue = {7},

pages = {e1061-e1074},

publisher = {Lancet Glob Health},

abstract = {Background: Malaria infections during pregnancy can cause adverse birth outcomes, yet many infections are undetected by microscopy. We aimed to describe the epidemiology of submicroscopic malaria infections in pregnant women in Asia, the Americas, and Africa using aggregated and individual participant data (IPD). Methods: For this systematic review and meta-analysis, studies (published Jan 1, 1997 to Nov 10, 2021) with information on both microscopic and submicroscopic infections during pregnancy from Asia, the Americas, or Africa, identified in the Malaria-in-Pregnancy Library, were eligible. Studies (or subgroups or study groups) that selected participants on the basis of the presence of fever or a positive blood smear were excluded to avoid selection bias. We obtained IPD (when available) and aggregated data. Estimates of malaria transmission intensity and sulfadoxine\textendashpyrimethamine resistance, matched by study location and year, were obtained using publicly available data. One-stage multivariable logit and multinomial models with random intercepts for study site were used in meta-analysis to assess prevalence of and risk factors for submicroscopic infections during pregnancy and at delivery. This study is registered with PROSPERO, number CRD42015027342. Findings: The search identified 87 eligible studies, 68 (78%) of which contributed to the analyses. Of these 68 studies, 45 (66%) studies contributed IPD (48 869 participants) and 23 (34%) studies contributed aggregated data (11 863 participants). During pregnancy, median prevalence estimates were 13·5% (range 0·0\textendash55·9, 66 substudies) for submicroscopic and 8·0% (0·0\textendash50·6, 66 substudies) for microscopic malaria. Among women with positive Plasmodium nucleic acid amplification tests (NAATs), the median proportion of submicroscopic infections was 58·7% (range 0·0\textendash100); this proportion was highest in the Americas (73·3%, 0·0\textendash100), followed by Asia (67·2%, 36·4\textendash100) and Africa (56·5%, 20·5\textendash97·7). In individual patient data analysis, compared with women with no malaria infections, those with submicroscopic infections were more likely to present with fever in Africa (adjusted odds ratio 1·32, 95% CI 1·02\textendash1·72; p=0·038) but not in other regions. Among women with NAAT-positive infections in Asia and the Americas, Plasmodium vivax infections were more likely to be submicroscopic than Plasmodium falciparum infections (3·69, 2·45\textendash5·54; p\<0·0001). Risk factors for submicroscopic infections among women with NAAT-positive infections in Africa included older age (age ≥30 years), multigravidity, and no HIV infection. Interpretation: During pregnancy, submicroscopic infections are more common than microscopic infections and are associated with fever in Africa. Malaria control in pregnancy should target both microscopic and submicroscopic infections. Funding: Bill \& Melinda Gates Foundation through the Worldwide Antimalarial Resistance Network.},

keywords = {{Adult, Anna Maria van Eijk, Antimalarials* / therapeutic use, Author(firstnames='Achille', Author(firstnames='Alain', Author(firstnames='Alassane', Author(firstnames='Alfredo', Author(firstnames='Almahamoudou', Author(firstnames='Ana', Author(firstnames='Anna', Author(firstnames='Annie', Author(firstnames='Ayola A', Author(firstnames='Azucena', Author(firstnames='Bernard A', Author(firstnames='Blair J', Author(firstnames='Blaise', Author(firstnames='Brian', Author(firstnames='Camila', Author(firstnames='Carlo', Author(firstnames='Carole', Author(firstnames='Chetan', Author(firstnames='Christopher L', Author(firstnames='Clara', Author(firstnames='Daniel', Author(firstnames='Dhanpat Kumar', Author(firstnames='Diane Wallace', Author(firstnames='Djimon M', Author(firstnames='Dominic', Author(firstnames='Don', Author(firstnames='Eliana Mar\'{i}a', Author(firstnames='Emmanual', Author(firstnames='Enesia Banda', Author(firstnames='Esperanca', Author(firstnames='Eusebio', Author(firstnames='Feiko O', Author(firstnames='Felix', Author(firstnames='Flor Ernestina', Author(firstnames='Francine', Author(firstnames='Francis', Author(firstnames='Frank P', Author(firstnames='Ghyslain', Author(firstnames='Gilles', Author(firstnames='Grant', Author(firstnames='Hallidou', Author(firstnames='Harry', Author(firstnames='Henk D', Author(firstnames='Holger W', Author(firstnames='Indu', Author(firstnames='Inoni', Author(firstnames='Ivo', Author(firstnames='Jenny', Author(firstnames='Jessica', Author(firstnames='Johanna H', Author(firstnames='Julie R', Author(firstnames='Kasia', Author(firstnames='Kassoum', Author(firstnames='Katherine R', Author(firstnames='Ken', Author(firstnames='Kephas', Author(firstnames='Lauren M', Author(firstnames='Linda', Author(firstnames='Lise', Author(firstnames='Maha A', Author(firstnames='Maminata', Author(firstnames='Manfred', Author(firstnames='Mar\'{i}a Eugenia', Author(firstnames='Maria', Author(firstnames='Martin', Author(firstnames='Meghna', Author(firstnames='Michal', Author(firstnames='Michel', Author(firstnames='Michela', Author(firstnames='Miriam K', Author(firstnames='Mwayiwawo', Author(firstnames='Myriam', Author(firstnames='Nadine', Author(firstnames='Nicaise', Author(firstnames='Norma', Author(firstnames='Olabisi A', Author(firstnames='Patrick E', Author(firstnames='Paul', Author(firstnames='Paulo', Author(firstnames='Per', Author(firstnames='Petra', Author(firstnames='Praveen K', Author(firstnames='R Matthew', Author(firstnames='Raquel', Author(firstnames='Rella', Author(firstnames='Rose F', Author(firstnames='Rosemary', Author(firstnames='Rukhsana', Author(firstnames='Sarah H', Author(firstnames='Sergi', Author(firstnames='Sonia M', Author(firstnames='Sonia', Author(firstnames='Stephanie K', Author(firstnames='Stephen J', Author(firstnames='Stephen R', Author(firstnames='Steve M', Author(firstnames='Susana', Author(firstnames='Swati', Author(firstnames='Ulla', Author(firstnames='Umberto', Author(firstnames='Valerie', Author(firstnames='Vera', Author(firstnames='Xavier', Author(firstnames='Yue', CollabAuthor(name='Subpatent Malaria in Pregnancy Group', Falciparum* / drug therapy, Female, Humans, Kasia Stepniewska, Malaria, Malaria* / prevention \& control, MEDLINE, Meta-Analysis, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, Non-U.S. Gov't, P.H.S., PMC10880462, Pregnancy, Prevalence, PubMed Abstract, Research Support, Risk Factors, Systematic review, U.S. Gov't},

pubstate = {published},

tppubtype = {article}

}

@article{Sondo2023,

title = {Enhanced effect of seasonal malaria chemoprevention when coupled with nutrients supplementation for preventing malaria in children under 5 years old in Burkina Faso: a randomized open label trial},

author = {Paul Sondo and B\'{e}renger Kabor\'{e} and Toussaint Rouamba and Eulalie Compaor\'{e} and Yssimini Nad\`{e}ge Guill\`{e}ne Tibiri and Hyacinthe Abd El Latif Fa\"{i}\c{c}al Kabor\'{e} and Karim Derra and Marc Christian Tahita and Hamidou Ilboudo and Gauthier Tougri and Isma\"{i}la Bouda and Tikanou Dakyo and Hyacinthe Kafando and Florence Ou\'{e}draogo and Eli Rouamba and So Franck Hien and Adama Kazienga and Cheick Sa\"{i}d Compaor\'{e} and Estelle Bambara and Macaire Nana and Prabin Dahal and Franck Garanet and William Kabor\'{e} and Thierry L\'{e}f\`{e}vre and Philippe Guerin and Halidou Tinto},

url = {https://pubmed.ncbi.nlm.nih.gov/37853408/},

doi = {10.1186/S12936-023-04745-6},

issn = {1475-2875},

year  = {2023},

date = {2023-01-01},

journal = {Malaria journal},

volume = {22},

issue = {1},

publisher = {Malar J},

abstract = {Background: In rural African settings, most of the children under the coverage of Seasonal Malaria Chemoprevention (SMC) are also undernourished at the time of SMC delivery, justifying the need for packaging malarial and nutritional interventions. This study aimed at assessing the impact of SMC by coupling the intervention with nutrients supplementation for preventing malaria in children less than 5 years old in Burkina Faso. Methods: A randomized trial was carried out between July 2020 and June 2021 in the health district of Nanoro, Burkina Faso. Children (n = 1059) under SMC coverage were randomly assigned to one of the three study arms SMC + Vitamin A (SMC-A},

keywords = {Antimalarials* / therapeutic use, B\'{e}renger Kabor\'{e}, Burkina Faso / epidemiology, Chemoprevention, Child, Cross-Sectional Studies, Dietary Supplements, doi:10.1186/s12936-023-04745-6, Halidou Tinto, Humans, Infant, Malaria* / epidemiology, MEDLINE, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, Nutrients, Paul Sondo, PMC10585892, pmid:37853408, Preschool, PubMed Abstract, Randomized controlled trial, Seasons, Vitamin A / therapeutic use},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {A Bayesian spatio-temporal framework to assess the effect of seasonal malaria chemoprevention on children under 5 years in Cameroon from 2016 to 2021 using routine data},

author = {Arnold Fottsoh Fokam and Toussaint Rouamba and Sekou Samadoulougou and Yazoume Ye and Fati Kirakoya-Samadoulougou},

url = {https://pubmed.ncbi.nlm.nih.gov/37951942/},

doi = {10.1186/S12936-023-04677-1},

issn = {1475-2875},

year  = {2023},

date = {2023-01-01},

journal = {Malaria journal},

volume = {22},

issue = {1},

publisher = {Malar J},

abstract = {Background: Malaria affects millions of Cameroonian children under 5 years of age living in the North and Far North regions. These regions bear the greatest burden, particularly for children under 5 years of age. To reduce the burden of disease in these regions, Cameroon adopted the Seasonal Malaria Chemoprevention (SMC) in 2016 and has implemented it each year since its adoption. However, no previous studies have systematically assessed the effects of this intervention in Cameroon. It is important to understand its effect and whether its implementation could be improved. This study aimed to assess the effect of SMC in Cameroon during the period 2016\textendash2021 on malaria morbidity in children under 5 years of age using routine data. Methods: Data on malaria cases were extracted from the Cameroon Health Monitoring Information System (HMIS) from January 1, 2011, to December 31, 2021. Health facilities report these data monthly on a single platform, the District Health Information System version 2 (DHIS2). Thus, a controlled interrupted time-series model in a Bayesian framework was used to evaluate the effects of the SMC on malaria morbidity. Results: SMC implementation was associated with a reduction in the incidence of uncomplicated malaria cases during the high-transmission periods from 2016 to 2021. Regarding the incidence of severe malaria during the high-transmission period, a reduction was found over the period 2016\textendash2019. The highest reduction was registered during the second year of implementation in 2017:15% (95% Credible Interval, 10\textendash19) of uncomplicated malaria cases and 51% (47\textendash54) of confirmed severe malaria cases. Conclusion: The addition of SMC to the malaria intervention package in Cameroon decreased the incidence of uncomplicated and severe malaria among children under 5 years of age. Based on these findings, this study supports the wide implementation of SMC to reduce the malaria burden in Cameroon as well as the use of routine malaria data to monitor the efficiency of the strategy in a timely manner.},

keywords = {Antimalarials* / therapeutic use, Arnold Fottsoh Fokam, Bayes Theorem, Cameroon / epidemiology, Chemoprevention, Child, doi:10.1186/s12936-023-04677-1, Fati Kirakoya-Samadoulougou, Humans, Infant, Malaria* / drug therapy, Malaria* / epidemiology, Malaria* / prevention \& control, MEDLINE, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, PMC10640753, pmid:37951942, Preschool, PubMed Abstract, Seasons, Toussaint Rouamba},

pubstate = {published},

tppubtype = {article}

}